Can we quantify the quality of vision?

Article

The age of refractive surgery has introduced new aberrations to the human eye that require a shift in how visual performance is evaluated, said Ray Applegate, MD. Mesopic low contrast acuity best quantifies vision quality; it overcomes the weaknesses of other metrics and it can predict visual function among individuals.

The age of refractive surgery has introduced new aberrations to the human eye that require a shift in how visual performance is evaluated, said Ray Applegate, MD. Mesopic low contrast acuity best quantifies vision quality; it overcomes the weaknesses of other metrics and it can predict visual function among individuals.

Dr Applegate recruited 168 people with 6/6 or better vision across a range of ages and conducted a photopic high-contrast logMAR acuity test. "The test could only account for around 4% of the variation in our sample," he said. "We can't use it to predict the visual function of individuals. However mesopic low-contrast logMAR acuity accounted for a much broader range of the variation."

Dr Applegate said high contrast acuity is a poor metric because it is conducted under high luminance conditions and has excess contrast allowing a loss in contrast and image fidelity without a loss in measured acuity.

Contrast sensitivity, on the other hand, is impractical because it requires measurements along many different orientations. "That is simply not practical in the clinical environment and it is totally insensitive to phase shifts," insisted Applegate.

But mesopic low contrast acuity allows a large physiologic pupil and is sensitive to phase shifts and contrast loss. "It's also a recognition task as opposed to a detection task that's understood by clinicians and patients and it's easy to administer in a clinical setting," he said.

The study will be published shortly in Optometry and Vision Science.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.